Mibolerone
Appearance
Clinical data | |
---|---|
Other names | (7R,8R,9S,10R,13S,14S,17S)-17-Hydroxy-7,13,17-trimethyl-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one |
AHFS/Drugs.com | International Drug Names |
Routes of administration | Oral |
ATC code |
|
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Metabolism | Hepatic |
Elimination half-life | 2-4 hours |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.020.951 |
Chemical and physical data | |
Formula | C20H30O2 |
Molar mass | 302.4558 g/mol g·mol−1 |
3D model (JSmol) | |
| |
| |
|
Mibolerone is a potent anabolic steroid which is both higher affinity[1] and more selective[2] for the androgen receptor than metribolone.
References
- ^ Murthy LR, Johnson MP, Rowley DR, Young CY, Scardino PT, Tindall DJ (1986). "Characterization of steroid receptors in human prostate using mibolerone". Prostate. 8 (3): 241–53. doi:10.1002/pros.2990080305. PMID 2422638.
{{cite journal}}
: CS1 maint: multiple names: authors list (link) - ^ Schilling K, Liao S (1984). "The use of radioactive 7 alpha, 17 alpha-dimethyl-19-nortestosterone (mibolerone) in the assay of androgen receptors". Prostate. 5 (6): 581–8. doi:10.1002/pros.2990050603. PMID 6333679.